Table 3.

Profiles of metachronous multiple remnant gastric cancer patients

No.	Group	ISP	Treatment	MTMC	Curability1	MRSC	PROG2
1	SNNS	SG	DG	50.5	Curative	75.6	Pneumonia
2	SNNS	SG	ESD	60.2	Curative	114.9	Alive
3	SNNS	SG	ESD	22.9	Curative	79.9	Alive
4	SNNS	MPG	ESD	13.6	Curative	76.3	Alive
5	SNNS	LR	ESD	30.7	Curative	73.1	Alive
6	SNNS	DG	TG	43.6	Curative	62.9	Alive
7	Control	DG	TG	19.5	Curative	63.6	Alive
8	Control	DG	TG	17.2	Curative	97.4	Alive
9	Control	DG	ESD	44.3	Curative	55.5	AID
10	Control	DG	ESD	220.4	Curative	240.0	Alive
11	Control	DG	ESD	40.6	Curative	120.0	Alive
12	Control	PG	UR	74.3	UR	120.0	Alive
13	Control	PG	TG	76.8	Curative	120.0	Alive
14	Control	PG	ESD	18.5	Curative	120.0	Alive
15	Control	PG	ESD	28.2	Curative	120.0	Alive
16	Control	PPG	TG	50.8	Curative	120.0	Alive
17	Control	PPG	DG	85.0	Curative	116.2	Alive
18	Control	PPG	ESD	77.1	Curative	118.5	Alive
19	Control	PPG	ESD	22.0	Curative	98.2	Alive
20	Control	LR	DG	7.6	Cure	42.8	CVD
21	Control	LR	ESD	64.2	Cure	85.7	Alive

¹“Curability” column indicates whether treatment for metachronous multiple remnant gastric cancers was curative or not. All but one unresectable patient could be resected radically, and there were no recurrences of metachronous gastric cancer. One unresectable patient was alive with metachronous cancer 10 years after the initial surgery.

²“PROG” column indicates whether the patients are alive at the time of recent survival confirmation, or the cause of death.

ISP: Initial surgical procedure; SG: Segmental gastrectomy; MPG: Mini-proximal gastrectomy; LR: Local resection; DG: Distal gastrectomy; PG: Proximal gastrectomy; PPG: Pylorus-preserving gastrectomy; ESD: Endoscopic submucosal dissection; TG: Total gastrectomy; UR: Unresectable; MTMC: Months to treat metachronous gastric cancer; MRSC: Months to recent survival confirmation; PROG: Prognosis or cause of death; AID: Autoimmune disease; CVD: Cerebrovascular disease; SNNS: Sentinel node navigation surgery.